1471 related articles for article (PubMed ID: 12627216)
1. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
3. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
[TBL] [Abstract][Full Text] [Related]
4. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
5. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.
Smith MR; Goode M; Zietman AL; McGovern FJ; Lee H; Finkelstein JS
J Clin Oncol; 2004 Jul; 22(13):2546-53. PubMed ID: 15226323
[TBL] [Abstract][Full Text] [Related]
6. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
Deng J; Li W; Yang L; Wang L; Zou D
Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
8. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Isahaya E; Hara N; Nishiyama T; Hoshii T; Takizawa I; Takahashi K
Prostate; 2010 Feb; 70(2):155-61. PubMed ID: 19760629
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
10. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis during androgen deprivation therapy for prostate cancer.
Smith MR
Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
[TBL] [Abstract][Full Text] [Related]
12. Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
Morabito N; Gaudio A; Lasco A; Catalano A; Atteritano M; Trifiletti A; Anastasi G; Melloni D; Frisina N
J Bone Miner Res; 2004 Nov; 19(11):1766-70. PubMed ID: 15476575
[TBL] [Abstract][Full Text] [Related]
13. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
14. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
[TBL] [Abstract][Full Text] [Related]
16. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
Deng JH; Yang LP; Wang LS; Zhou DF
Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
[TBL] [Abstract][Full Text] [Related]
17. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
[TBL] [Abstract][Full Text] [Related]
18. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation in prostate cancer and the long-term risk of fracture.
Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC
Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363
[TBL] [Abstract][Full Text] [Related]
20. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.
Morote J; Orsola A; Abascal JM; Planas J; Trilla E; Raventos CX; Cecchini L; Encabo G; Reventos J
J Urol; 2006 May; 175(5):1679-83; discussion 1683. PubMed ID: 16600728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
